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ABSTRACT 
ANTICHOLINERGIC IMPACT ON COGNITION IN SCHIZOPHRENIA 
 
This secondary analysis examined the relationship between the total anticholinergic load 
and scores on cognitive tests in 94 patients diagnosed with schizophrenia or schizoaffective 
disorder.  Cognitive impairment is a core feature of schizophrenia, and studies have shown that it 
is a strong predictor of functional outcomes in this population.  Anticholinergic medications have 
been demonstrated to have a negative impact on cognition.  Some antipsychotic medications 
have anticholinergic properties, and anticholinergic medications are often prescribed to patients 
with schizophrenia to treat or prevent extrapyramidal side effects of antipsychotics.  We did not 
find any significant correlations between anticholinergic load as measured by benztropine 
equivalents and any of the MATRICS cognitive tests.  In addition there were no significant 
differences in the mean scores of subjects in the highest anticholinergic quartile and subjects in 
the lowest anticholinergic quartile.  These same analyses were performed comparing 
chlorpromazine equivalents and again there were no statistically significant results.  Our results 
suggest that the anticholinergic load or dose of antipsychotic medication do not significantly 
contribute to cognitive deficits in patients with schizophrenia or schizoaffective disorder.  The 
relatively small sample size was inadequate to detect a small difference. 
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Introduction 
Schizophrenia is a chronic psychiatric disorder affecting about 1% of the population 
worldwide.  Although it is most often characterized by the positive and negative symptoms, 
impaired cognition is also a core feature of this disorder (Goldberg & Green, 2002; Velligan & 
Miller, 1999; Sharma & Antonova, 2003; O’Carroll, 2000.  It is likely that these deficits in 
cognition predate the onset of positive or negative symptomatology (Green, 1996).  Patients 
experiencing their first psychotic episode and patients with chronic schizophrenia perform poorly 
on tests of memory, executive functioning and attention (Goldberg & Green, 2002). Over the 
past decade, treatments for schizophrenia are increasingly targeting cognitive impairments 
(Fumagalli, Frasca, Racagni, & Riva, 2009; Weiss, Bilder, & Fleischhacker, 2002; Velligan & 
Miller, 2003). 
In patients with schizophrenia, cognitive abilities predict and correlate with functional 
outcome (Green, 1996; Goldberg & Green, 2002; Kurtz, Wexler, Fujimoto, Shagan, & Seltzer, 
2008; Weiss et al., 2002), more strongly than psychotic symptoms (Green, 1996).  Specifically, 
secondary verbal memory (delayed recall as opposed to immediate recall) is a strong predictor of 
functional outcome regardless of which specific functional task is being measured (Green, 1996).  
Additionally, there is evidence that employment is predicted by speed of processing, (with this 
predictive power improving with the addition of visual learning and attention/vigilance 
assessment scores) (Kern et al., 2011) and working memory performance (Shamsi et al., 2011).  
Skill acquisition is associated with verbal memory and vigilance (Green, 1996) and social 
functioning is predicted by social cognition and attention (Shamsi et al., 2011) and vigilance 
(Green, 1996). 
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It is not uncommon for patients with schizophrenia to be prescribed anticholinergic 
medications.  Anticholinergic medications inhibit acetylcholine activity by occupying its 
receptors.  There is particular interest in the muscarinic subtype of acetylcholine receptors, as it 
is these receptors, rather than the nicotinic subtype, upon which psychiatric medications 
demonstrate activity.  Scopolamine, an anticholinergic medication, is used in 
neuropsychopharmacological studies to induce cognitive deficits in humans and animals 
(Klinkenberg & Blokland, 2010).  Acetylcholine receptor antagonists decrease muscle tremors 
and rigidity and are often used to prevent or treat extrapyramidal symptoms in patients on 
antipsychotics.  Campbell et al. (2009) systematically reviewed 27 studies and found a consistent 
association between cognitive impairments in older adults and the use of anticholinergic 
medications.  Specifically, exposure to anticholinergic medications was found to correlate with 
deficits in speed of processing, concentration and attention, problem-solving (Campbell et al., 
2009) and verbal memory (Brebion, Bressan, Amador, Malaspina, & Gorman, 2004). 
Antipsychotic medications, which are prescribed for the treatment of schizophrenia, may 
also have anticholinergic properties (Ozbilen & Adams, 2009).  In addition, many patients are on 
more than one antipsychotic at a time (Zink, Englisch, & MeyerLindenberg, 2010).  Are we 
prescribing psychiatric medications that contribute to the cognitive impairment of patients with 
schizophrenia? 
Vinogradov, Fisher, Warm, Holland, Kirshner, and Pollock (2009) examined the 
relationship between the anticholinergic load of medications taken and the response to cognitive 
training in 55 patients.   The patients were randomly assigned to either auditory cognitive 
computer training or a computer games control condition.  Measurement and Treatment 
Research to Improve Cognition in Schizophrenia (MATRICS)-recommended measures were 
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administered at baseline and after intervention.   Blood samples were obtained at baseline for all 
participants, and a radioreceptor binding assay was used to determine serum anticholinergic 
activity.  Blood samples taken at 10 weeks from a random sample of participants indicated that 
serum anticholinergic levels remained constant throughout the study.   For all participants at 
baseline, there was a significant negative correlation between anticholinergic activity as 
measured by serum levels and verbal working memory (r = –0.41, p<0.04) and verbal learning 
and memory (r = –0.29, p<0.04).  In verbal working memory, 56% variance was attributed to 
anticholinergic activity, age, IQ, and symptom severity with 37% variance attributed to these 
same factors in verbal learning and memory.  In both domains, 7% of the variance was uniquely 
attributed to anticholinergic load, independent of the other factors.  In the intervention group, 
anticholinergic load was demonstrated to have a significant negative impact on participants’ 
response to cognitive training (Pearson’s r = –0.46, p<0.02).  In this group, anticholinergic 
activity uniquely accounted for 20% of the variance in cognitive change, which is significantly 
more than age, IQ, or symptom severity accounted for.  Additionally, participants with lower 
anticholinergic activity had greater cognitive gains after cognitive remediation, a treatment 
aimed to improve cognitive problems. 
 The present analysis is a post-hoc analysis of a larger on-going study of cognitive 
remediation's effects on vocational outcomes in schizophrenia and schizoaffective disorder. The 
purpose of this secondary analysis is to test whether anticholinergic load is associated with lower 
cognitive performance on tests of verbal learning and working memory. 
Methods 
Setting and Subjects 
This secondary analysis included 94 adult outpatients (male=54, female=40) with 
schizophrenia (n=65) or schizoaffective disorder (n=27), who participated in a randomized 
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controlled trial combining computerized-based cognitive remediation with vocational 
rehabilitation at a community mental health center in Connecticut.  Diagnoses were made 
following a clinical assessment.  Inclusion and exclusion criteria for the main study are as 
follows: diagnosis of schizophrenia or schizoaffective disorder, no history of head trauma, no 
history of epilepsy, loss of consciousness; developmental delay; mental retardation, clinically 
stable (no hospitalization or medication change in the past month), no active abuse of substances 
in the past 60 days, stable housing (no housing changes in the last 30 days), interested in 
obtaining competitive employment in the community, willing to do cognitive training if 
randomized to that condition.  
The main study has not yet been published, but one post-hoc analysis has been described 
in Surti, Corbera, Bell, and Wexler (2011).  The main study included 98 total patients, but four 
were left out of our secondary analysis: one patient was simultaneously engaged in a double-
blind, placebo-controlled, antipsychotic medication study; and three patients had incomplete 
medication information.   
Procedures 
Upon intake and at each follow-up in the main study, participants completed a history 
form that included a concomitant medication record.  These records were verified against 
participants’ ongoing treatment records in 79.8% of cases (n=75).  Eighty-eight of 94 
participants were on psychiatric medications.  Using recorded data, chlorpromazine and 
benztropine equivalents were calculated for each patient.  Chlorpromazine dose equivalency 
calculations were done using ratios from Andreasen, Pressler, Nopoulos, Miller, and Ho (2010). 
This method used expert consensus and regression equations to derive formulas for each drug’s 
potency relative to chlorpromazine.  The dosage of each antipsychotic medication was multiplied 
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by its respective ratio to ascertain its equivalence to 100mg of chlorpromazine.  If a patient was 
on multiple antipsychotics, the chlorpromazine equivalences of each medication were added 
together to derive the patient’s total chlorpromazine load.  Benztropine equivalents were 
calculated for all patients on psychiatric medications (antipsychotics, antidepressants and 
anticholinergics) known to have anticholinergic activity.  Benztropine equivalents were 
calculated using ratios from Minzenberg, Poole, Benton, and Vinogradov (2004) in which the 
average anticholinergic activity (as determined by binding affinity gathered from published 
studies reporting in vitro brain muscarinic receptor antagonism) of a medication was compared 
with that of benztropine (1mg) to determine a pharmacological index.  Each patient’s medication 
dosages were multiplied by this index to generate a total for each patient.  Chlorpromazine 
equivalents for paliperidone and molindone, unavailable in the two previous studies, were 
calculated using beginning dosage information from the respective manufacturers.  Neither drug 
exhibits appreciable affinity for muscarinic receptors (Janicak & Winans, 2007; Richelson & 
Nelson, 1984).   
Measures 
The National Institute of Mental Health (NIMH) designed the MATRICS initiative to 
support pharmacological treatment of cognitive deficits in schizophrenia.  One goal for this 
consensus battery of cognitive tests was to permit comparisons across medication trials.   The 
MATRICS Neurocognition Committee selected 10 tests that demonstrated similar effects among 
5 study sites, high test-retest reliability, utility as a repeated measure, relationship to functional 
outcome, and practicality and tolerability (Neuchterlein et al., 2008).   These tests cover seven 
domains of cognition: speed of processing, attention/vigilance, working memory, verbal 
learning, visual learning, reasoning and problem-solving, and social cognition (determined to be 
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replicable across studies and represent fundamental dimensions of cognitive deficit in 
schizophrenia [Neuchterlein et al., 2004]).  This MATRICS Consensus Cognitive Battery 
(MCCB) (Neuchterlein et al., 2008; Kern et al., 2008) has been used in large multi-site trials 
(Keefe et al., 2011) and has been shown to be a sensitive tool for assessing the extent of 
cognitive impairment in schizophrenia (August, Kiwanuka, McMahon, & Gold, 2012).  
In the current study trained psychometricians administered the MCCB to participants at 
intake and at each follow-up visit. 
Analytic Strategy  
 Baseline characteristics were examined to evaluate the distribution on demographic and 
clinical variables, as well as the medication status and performance on MATRICS battery.   The 
correlation of chlorpromazine and benztropine values with overall composite t-scores on the 
MCCB at baseline was examined using Spearman’s rho, as the data are were not normally 
distributed.  Based on the findings of Vinogradov et al. (2009), additional correlations were 
calculated to evaluate correlations between benztropine/chlorpromazine loads and both t-scores 
and raw scores of the MCCB subtests.  Finally, independent t-tests were used to determine 
whether subjects in the highest quartiles on chlorpromazine and benztropine levels had greater 
cognitive impairment than those in the lowest quartiles as evidenced by lower scores on the 
Hopkins Verbal Learning Test (HVLT) and the Letter Number Span (LNS) test, MCCB subtests 
of verbal learning and working memory, respectively.  P value was set at 0.05 for all tests, using 
two-tailed tests. 
Results 
Table 1 shows the demographic information on the participants included in this 
secondary analysis.  T-tests were run comparing demographic variables: male versus female 
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participants, paranoid schizophrenia versus all other participant diagnoses, African-American 
versus all other participant ethnicities, and single status versus all other participant marital 
statuses.  No significant difference emerged with exception of comparisons of African-American 
participants versus the other samples.  For example, the chlorpromazine load for African-
American subjects (m = 520.33 ± 435.15) was significantly higher than that of the other subjects 
(m = 321.98 ± 228.27), t(83.95) = -2.86, p < .05.  Although it was interesting that this population 
also had lower benztropine equivalents (m = 4.05 ± 12.77) than the rest of the participants (m = 
11.09 ± 21.34), this difference was not statistically significant, t(59.34) = 1.86, p > .05.  
Comparisons of the mean t-scores of the MCCB tests demonstrated significant differences 
between ethnicities.  On the overall composite score African-American participants had a mean 
score of 24.17 ± 10.91 compared to 32.78 ± 12.53 for the other ethnicities, t(92) = 3.55, p < .05.  
On the HVLT test African-American participants had a mean score of 33.83 ± 6.95 compared to 
37.83 ± 8.47 for the other ethnicities, t(92) = 2.51, p < .05.  On the LNS test African-American 
participants had a mean score of 33.37 ± 12.06 compared to 41.63 ± 10.38 for the other 
ethnicities, t(92) = 3.48, p < .05.  Table 2 displays further clinical characteristics of the entire 
sample. 
Of the 94 total patients, 88 were on antipsychotic medications, and 60 patients were on 
medications with demonstrable anticholinergic activity.  Table 3 lists all medications prescribed 
to the participants, the number of milligrams of that medication equal to 100mg of 
chlorpromazine and 1mg of benztropine (where applicable), as well as the number of patients in 
the study on each drug. Each patient had an MCCB composite score as well as individual raw 
scores and t-scores for each of the subtests.   When we compared the anticholinergic load to our 
patients’ scores on cognitive tests, we found no significant correlation with global cognition, the 
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t-scores, or the raw scores of any subtest.  We also found no significant correlation between any 
cognitive scores and our patients’ chlorpromazine equivalents.  Spearman correlations and their 
significance are shown in Tables 4 and 5.   
Figures 1 and 2 show the distribution of the participants chlorpromazine and benztropine 
loads.  The data are not normally distributed, and many patients were in the lower end (smaller 
daily dose equivalents) for both chlorpromazine and benztropine.  We compared the mean scores 
on the HVLT and LNS of those patients in the highest quartile to those in the lowest quartile for 
both chlorpromazine and benztropine.  Those two subtests were chosen as we would expect to 
see the largest anticholinergic effect on the domains of verbal learning and working memory. 
The independent-samples t-test comparing the mean HVLT t-score in subjects in the 
highest chlorpromazine quartile (m = 35.00 ± 8.71) to the mean HVLT t-score of subjects in the 
lowest chlorpromazine quartile (m = 37.42 ± 7.44) found no significant difference, t(45) = 1.024, 
p > .05.  Another independent-samples t-test was calculated to compare the mean LNS t-scores 
of subjects in the highest and lowest chlorpromazine quartiles.  No significant difference was 
found, t(45) = 1.692, p > .05.  The mean scores of the highest quartile (m = 40.54 ± 11.47) were 
not significantly different from those of the lowest quartile (m = 34.43 ± 13.24). 
Likewise, an independent-samples t-test was calculated comparing the mean HVLT t-
score of subjects in the highest benztropine quartile (m = 34.70 ± 8.13) to the mean HVLT t-
score of subjects in the lowest benztropine quartile (m = 36.82 ± 8.41).  Again, no significant 
difference emerged, t(58) = .987, p > .05.  Another independent-samples t-test was calculated to 
compare the mean LNS t-scores of subjects in the highest and lowest benztropine quartiles.  No 
significant difference was found, t(58) = 1.048, p > .05.  The mean scores of the highest quartile 
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(m = 35.81 ± 10.80) were not significantly different from those of the lowest quartile (m = 38.91 
± 11.78). 
Discussion 
Of the 94 subjects in this sample, 88 had data on drug treatment and cognitive test 
performance. There were not  significant differences in test scores or medication loads based on 
any demographic variables, with the exception of African American participants having higher 
chlorpromazine equivalents, lower composite scores, and lower HVLT and LNS t-scores than 
participants of other ethic groups.  Subjects in this sample of all demographic variables were on a 
range of antipsychotic medications and other agents that contributed to a wide range of 
anticholinergic load.  Our results show weak correlations between anticholinergic burden and 
MCCB scores at baseline (before cognitive intervention). In addition, t-tests comparing HVLT 
and LNS mean t-scores of those with the highest and lowest anticholinergic burden showed no 
statistical difference.  Nor was there a significant relationship between the total chlorpromazine 
equivalents of patients’ medication regimens and their performance on these same cognitive 
tests.  These findings are not consistent with those of Vinogradov et al. (2009) who found that 
anticholinergic activity impaired cognitive performance in working memory and verbal learning 
and memory.  In contrast to Vinogradov et al., who used a radioreceptor binding assay to 
determine serum anticholinergic activity, our equivalences were determined using estimations of 
anticholinergic activity based on prescribed medications.   In the absence of blood levels, we 
cannot be certain that subjects were taking those medications as prescribed.  However, our 
results are also inconsistent with those of Minzenberg et al. (2004) who used similar methods to 
determine the pharmacological indices.   In that study, Minzenberg et al. observed that greater 
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anticholinergic burden was associated with greater impairment in attention and declarative 
memory.  
Furthermore, we only have information on psychotropic medications, where patients may 
have been taking other non-psychiatric prescriptions or over the counter drugs that could have 
affected muscarinic receptors in the central nervous system.  For this preliminary study, we did 
not control for age, duration of illness or level of education, all of which could affect cognitive 
abilities.  We did not specifically control for IQ, but there is evidence that the summary of 
MCCB tests overlap with general intelligence (August et al., 2011).  Although we did not find an 
association between cognition and chlorpromazine equivalent, we did not specifically control for 
symptom severity.   
Similar to the findings of Vinogradov et al. and Minzenberg et al., our findings did not 
show a correlation between anticholinergic load and general cognition at baseline.  In 
Vinogradov’s study, however, anticholinergic load had a greater contribution to variance in the 
response of the subjects to change in cognition after remediation than to variance in baseline 
cognitive performance.  This indicates the possibility that anticholinergic burden has a more 
pronounced influence on the effects of cognitive remediation rather than on cognition at baseline, 
which could be examined in future research.   Our current results suggest, however, that the 
anticholinergic activity in psychiatric medications currently prescribed to this patient population 
may not significantly contribute to patients’ current cognitive deficits.  However, this was a 
relatively small, highly selected sample. Thus, these findings are vulnerable to a spurious finding 
of no difference. 
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Table 1 
Demographic Characteristics of 94 Study Participants  
              
Variable        N    %    
Gender 
 Male      54   57.4 
 Female     40   42.6 
Diagnosis 
 Schizophrenia, Paranoid   40   42.6 
 Schizophrenia, Disorganized   1   1.1 
 Schizophrenia, Residual   13   13.8 
 Schizophrenia, Undifferentiated  11   11.7 
 Schizoaffective Disorder   29   30.9 
Ethnicity 
 African-American    54   57.4 
 Caucasian     38   40.4 
 Hispanic     1   1.1 
 Other      1   1.1 
Marital Status 
 Single      77   81.9 
 Married     5   2.9 
 Separated/Divorced    11   11.7 
 Widowed     1   1.1 
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Table 2 
Clinical Characteristics of 94 Study Participants  
              
Variable      Mean   SD  Range   
Age       43.00  10.23  23 – 64  
Education (years)     12.70  2.43  8 – 25  
Duration of Illness (years)    21.49  12.06    1 – 50  
PANSS Positive Score    13.86  7.07  2 – 33 
PANSS Negative Score    13.16  7.03  1 – 29 
PANSS General Score    25.97  11.88  1 – 47 
Benztropine Equivalent    7.05  17.21  .00 – 77.00 
CPZ Equivalent     435.93  373.48  .00 – 2272.73 
HVLT t-score      35.44  7.71  23 – 60 
LNS t-score      36.58  11.99  0 – 64 
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Table 3  
Benztropine and Chlorpromazine Equivalents in Study Subjects at Baseline 
               
Medication      Benztropinea  Chlorpromazineb  #ofPtsc  
Antipsychotics 
Aripiprazole (Abilify)    6.42  _   14 
Clozapine (Clozaril)     8  108   13 
Olanzapine (Zyprexa)    17  4.75   14 
Risperidone (Risperdal)    _  1.32   14 
Quetiapine (Seroquel)    733   142   11 
Ziprasidone (Geodon)    _   50.5   8 
Haloperidol (Haldol)    _      1.84   4 
Chlorpromazine (Thorazine)   47  100   1 
Perphenazine (Trilafon)   1470  6.9   8 
Fluphenazine (Prolixin)   _  1.76   3 
Paliperidone (Invega)    _  6   1 
Molindone (Moban)    _  50   1 
Fluphenazine Decanoate (mg/2-3wks) _  7.91   6 
Haloperidol decanoate (mg/4 wks)  _  35.3   2 
Risperdal Consta (mg/2wks)   _  25   5 
Antidepressants 
Paroxetine (Paxil)    73  _   3 
Sertraline (Zoloft)    490  _   4 
Anti-parkinsonian agents 
Benztropine (Cogentin)   1  _   23 
Diphenhydramine (Benadryl)   147  _   1 
Trihexyphenidyl (Artane)   1.6  _   3 
              
aBenztropine 1mg is equal to the number of milligrams listed for each drug 
bChlorpromazine 100mg is equal to the number of milligrams listed for each drug 
cTotal number of participants for whom each drug was prescribed  
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Table 4 
Spearman Correlations Between Cognitive Test T-Scores and Medication Equivalents 
              
 MCCBa Test   Benztropine   Chlorpromazine 
      rho (p value)   rho (p value)   
Composite Score    -0.119 (0.255)   -0.145 (0.163)   
Trail-Making     -0.172 (0.098)   -0.045 (0.665)   
Symbol Coding    0.014 (0.897)   -0.150 (0.149)  
Hopkins Verbal Learning Test  -0.133 (0.201)   -0.085 (0.416)   
Spatial Span     -0.027 (0.795)   -0.075 (0.473)   
Letter-Number Span    -0.104 (0.320)   -0.163 (0.116)  
Mazes      -0.103 (0.321)    0.028 (0.789)   
Brief Visual-Spatial Memory Test  -0.085 (0.413)   -0.121 (.245)   
Category Fluency    0.092 (0.380)   -0.062 (0.555)   
Managing Emotions    -0.124 (0.233)   -0.106 (0.311)   
Continuous Performance Test  -0.051 (0.625)   -0.145 (0.162)   
              
aMCCB =MATRICS Consensus Cognitive Battery 
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Table 5 
Spearman Correlations Between Cognitive Subtest Raw Scores and Medication Equivalents 
              
 MCCBa Test   Benztropine   Chlorpromazine 
      rho (p value)   rho (p value)   
Trail-Making     0.157 (0.130)   -0.002 (0.987)   
Symbol Coding    0.044 (0.673)   -0.057 (0.588)   
Hopkins Verbal Learning Test  -0.127 (0.223)   -0.078 (0.453)   
Spatial Span     -0.011 (0.914)   -0.009 (0.932)   
Letter-Number Span    -0.093 (0.374)   -0.133 (0.200)   
Mazes      -0.050 (0.634)   0.124 (0.234)   
Brief Visual-Spatial Memory Test  -0.042 (0.690)   -0.011 (.917)   
Category Fluency    0.099 (0.344)   -0.037 (0.722)   
Managing Emotions    -0.123 (0.237)   -0.117 (0.262)   
Continuous Performance Test  -0.032 (0.760)   -0.106 (0.307)   
              
aMCCB =MATRICS Consensus Cognitive Battery 
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Figure 1.  Distribution of the frequencies of participant total benztropine loads  
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Figure 2.  Distribution of the frequencies of participant total chlorpromazine loads  
